Xenon pharmaceuticals inc XENE.US 總覽分析
XENE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
XENE 近期報酬表現
-1.93%
Xenon pharmaceuticals inc
1.99%
同產業平均
-0.64%
S&P500
與 XENE 同產業的標的表現
- SNDX Syndax pharmaceuticals inc價值 2 分趨勢 3 分波段 5 分籌碼 4 分股利 1 分查看更多
XENE 公司資訊
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.